efinaconazole
(NFEZZTICAUWDHU-RDTXWAMCSA-N)
Structure
- SMILES
- C=C1CCN(CC1)[C@@H]([C@@](c1ccc(cc1F)F)(Cn1cncn1)O)C
- Type(s)
- Approved
- ATC code(s)
- D01AC19
- Molecular Formula:
- C18H22F2N4O
- Molecular Weight:
- 348.390
- Log P:
- 2.4225
- Hydrogen Bond Acceptor:
- 5
- Hydrogen Bond Donor:
- 1
- TPSA:
- 54.18
- CAS Number(s):
- 164650-44-6; 164905-19-5
Synonym(s)
1.
efinaconazole
2.
Jublia
3.
KP 103
4.
KP-103
5.
KP103
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Drug ineffective | FAERS: 145 Canada Vigilance: 50 | Canada Vigilance US FAERS | |
| 2 | Erythema | FAERS: 40 Canada Vigilance: 6 | Canada Vigilance US FAERS | |
| 3 | No adverse event | FAERS: 39 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 4 | Drug effect incomplete | FAERS: 38 | US FAERS | |
| 5 | Drug dose omission | FAERS: 32 | US FAERS | |
| 6 | Pruritus | FAERS: 21 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 7 | Application site pain | FAERS: 19 Canada Vigilance: 1 | Canada Vigilance SIDER US FAERS | |
| 8 | Accidental exposure to product | FAERS: 17 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 9 | Application site erythema | FAERS: 17 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 10 | Product quality issue | FAERS: 17 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 11 | Application site vesicles | FAERS: 15 Canada Vigilance: 1 | Canada Vigilance SIDER US FAERS | |
| 12 | Pain | FAERS: 15 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 13 | Swelling | FAERS: 14 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 14 | Burning sensation | FAERS: 13 | US FAERS | |
| 15 | Eye irritation | FAERS: 13 | US FAERS | |
| 16 | Drug administered at inappropriate site | FAERS: 11 | US FAERS | |
| 17 | Incorrect drug administration duration | FAERS: 10 | US FAERS | |
| 18 | Product use issue | FAERS: 10 Canada Vigilance: 5 | Canada Vigilance US FAERS | |
| 19 | Intentional product use issue | FAERS: 9 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 20 | Dermatitis | FAERS: 8 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 21 | Drug administration error | FAERS: 8 | US FAERS | |
| 22 | Peripheral swelling | FAERS: 8 | US FAERS | |
| 23 | Application site pruritus | FAERS: 7 | US FAERS | |
| 24 | Onychomycosis | FAERS: 7 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 25 | Application site swelling | FAERS: 6 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 26 | Onychoclasis | FAERS: 6 | US FAERS | |
| 27 | Overdose | FAERS: 6 | US FAERS | |
| 28 | Skin irritation | FAERS: 6 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 29 | Application site irritation | FAERS: 5 | US FAERS | |
| 30 | Application site rash | FAERS: 5 | SIDER US FAERS | |
| 31 | Dry skin | FAERS: 5 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 32 | Incorrect dose administered | FAERS: 5 | US FAERS | |
| 33 | Incorrect route of drug administration | FAERS: 5 | US FAERS | |
| 34 | Urticaria | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 35 | Expired product administered | FAERS: 4 | US FAERS | |
| 36 | Extra dose administered | FAERS: 4 | US FAERS | |
| 37 | Headache | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 38 | Medication Error | FAERS: 4 | US FAERS | |
| 39 | Onychalgia | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 40 | Product container issue | FAERS: 4 Canada Vigilance: 4 | Canada Vigilance US FAERS | |
| 41 | Product dropper issue | FAERS: 4 | US FAERS | |
| 42 | Product physical issue | FAERS: 4 | US FAERS | |
| 43 | Adverse event | FAERS: 3 | US FAERS | |
| 44 | Drug dispensing error | FAERS: 3 | US FAERS | |
| 45 | Dysgeusia | FAERS: 3 | US FAERS | |
| 46 | Fatigue | FAERS: 3 | US FAERS | |
| 47 | Hypersensitivity | FAERS: 3 | US FAERS | |
| 48 | Infection | FAERS: 3 | US FAERS | |
| 49 | Product label issue | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 50 | Product leakage | FAERS: 3 | US FAERS | |
| 51 | Product use in unapproved indication | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 52 | Rash erythematous | FAERS: 3 | US FAERS | |
| 53 | Wrong technique in product usage process | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 54 | Application site exfoliation | FAERS: 2 | US FAERS | |
| 55 | Application site inflammation | FAERS: 2 | US FAERS | |
| 56 | Arthralgia | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 57 | Asthenia | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 58 | Cellulitis | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 59 | Device defective | FAERS: 2 | US FAERS | |
| 60 | Discomfort | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 61 | Disease recurrence | FAERS: 2 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 62 | Drug prescribing error | FAERS: 2 | US FAERS | |
| 63 | Liquid product physical issue | FAERS: 2 | US FAERS | |
| 64 | Nail pigmentation | FAERS: 2 | US FAERS | |
| 65 | Onycholysis | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 66 | Product administered at inappropriate site | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 67 | Product physical consistency issue | FAERS: 2 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 68 | Skin Ulcer | FAERS: 2 | US FAERS | |
| 69 | Abasia | FAERS: 1 | US FAERS | |
| 70 | Administration site dryness | FAERS: 1 | US FAERS | |
| 71 | Alopecia | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 72 | Anxiety | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 73 | Apparent death | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 74 | Application site papules | FAERS: 1 | US FAERS | |
| 75 | Back Pain | FAERS: 1 | US FAERS | |
| 76 | Blindness | FAERS: 1 | US FAERS | |
| 77 | Blood pressure fluctuation | FAERS: 1 | US FAERS | |
| 78 | Chemical injury | FAERS: 1 | US FAERS | |
| 79 | Chest Pain | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 80 | Chest discomfort | FAERS: 1 | US FAERS | |
| 81 | Conjunctivitis | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 82 | Constipation | FAERS: 1 | US FAERS | |
| 83 | Cyst | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 84 | Device malfunction | FAERS: 1 | US FAERS | |
| 85 | Disability | FAERS: 1 | US FAERS | |
| 86 | Dizziness | FAERS: 1 | US FAERS | |
| 87 | Drug administered to patient of inappropriate age | FAERS: 1 | US FAERS | |
| 88 | Drug effect delayed | FAERS: 1 | US FAERS | |
| 89 | Drug ineffective for unapproved indication | FAERS: 1 | US FAERS | |
| 90 | Dyspepsia | FAERS: 1 | US FAERS | |
| 91 | Eye pain | FAERS: 1 | US FAERS | |
| 92 | Feeling abnormal | FAERS: 1 | US FAERS | |
| 93 | Feeling jittery | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 94 | Fungal paronychia | FAERS: 1 | US FAERS | |
| 95 | General physical health deterioration | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 96 | Genital infection fungal | FAERS: 1 | US FAERS | |
| 97 | Hypersomnia | FAERS: 1 | US FAERS | |
| 98 | Inability to afford medication | FAERS: 1 | US FAERS | |
| 99 | Inappropriate schedule of product administration | FAERS: 1 | US FAERS | |
| 100 | Incorrect route of product administration | FAERS: 1 | US FAERS | |
| 101 | Insurance issue | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 102 | Joint swelling | FAERS: 1 | US FAERS | |
| 103 | Limb discomfort | FAERS: 1 | US FAERS | |
| 104 | Limb injury | FAERS: 1 | US FAERS | |
| 105 | Maternal exposure during pregnancy | FAERS: 1 | US FAERS | |
| 106 | Medication residue present | FAERS: 1 | US FAERS | |
| 107 | Memory impairment | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 108 | Musculoskeletal chest pain | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 109 | Nail bed disorder | FAERS: 1 | US FAERS | |
| 110 | Nail bed infection | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 111 | Nervousness | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 112 | Pallor | FAERS: 1 | US FAERS | |
| 113 | Pneumonia | FAERS: 1 | US FAERS | |
| 114 | Poor quality drug administered | FAERS: 1 | US FAERS | |
| 115 | Prescription drug used without a prescription | FAERS: 1 | US FAERS | |
| 116 | Product availability issue | FAERS: 1 | US FAERS | |
| 117 | Product label confusion | FAERS: 1 | US FAERS | |
| 118 | Product packaging confusion | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 119 | Product packaging quantity issue | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 120 | Prostatic specific antigen decreased | FAERS: 1 | US FAERS | |
| 121 | Rosacea | FAERS: 1 | US FAERS | |
| 122 | Scab | FAERS: 1 Canada Vigilance: 5 | Canada Vigilance US FAERS | |
| 123 | Sinusitis | FAERS: 1 | US FAERS | |
| 124 | Skin hypertrophy | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 125 | Sleep disorder due to general medical condition, insomnia type | FAERS: 1 | US FAERS | |
| 126 | Sneezing | FAERS: 1 | US FAERS | |
| 127 | Stomatitis | FAERS: 1 | US FAERS | |
| 128 | Therapeutic product ineffective | FAERS: 1 | US FAERS | |
| 129 | Therapy cessation | FAERS: 1 | US FAERS | |
| 130 | Therapy non-responder | FAERS: 1 | US FAERS | |
| 131 | Throat irritation | FAERS: 1 | US FAERS | |
| 132 | Tinea Pedis | FAERS: 1 | US FAERS | |
| 133 | Tremor | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 134 | Ulcer | FAERS: 1 | US FAERS | |
| 135 | Unevaluable event | FAERS: 1 | US FAERS | |
| 136 | Vitreous floaters | FAERS: 1 | US FAERS | |
| 137 | Wrong drug administered | FAERS: 1 | US FAERS | |
| 138 | Application site burn | Canada Vigilance: 1 | Canada Vigilance | |
| 139 | Application site discharge | Canada Vigilance: 1 | Canada Vigilance | |
| 140 | Asthma | Canada Vigilance: 1 | Canada Vigilance | |
| 141 | Device use issue | Canada Vigilance: 1 | Canada Vigilance | |
| 142 | Incorrect product administration duration | Canada Vigilance: 4 | Canada Vigilance | |
| 143 | Inflammation | Canada Vigilance: 1 | Canada Vigilance | |
| 144 | Instillation site pain | SIDER | ||
| 145 | Palliative Care | Canada Vigilance: 1 | Canada Vigilance | |
| 146 | Pericardial effusion | Canada Vigilance: 1 | Canada Vigilance | |
| 147 | Product adhesion issue | Canada Vigilance: 1 | Canada Vigilance | |
| 148 | Product dose omission | Canada Vigilance: 1 | Canada Vigilance | |
| 149 | Product lot number issue | Canada Vigilance: 1 | Canada Vigilance | |
| 150 | Product prescribing error | Canada Vigilance: 1 | Canada Vigilance | |
| 151 | Skin reaction | Canada Vigilance: 1 | Canada Vigilance | |
| 152 | Skin texture abnormal | Canada Vigilance: 1 | Canada Vigilance | |
| 153 | Therapeutic product effect incomplete | Canada Vigilance: 2 | Canada Vigilance | |
| 154 | Wrong dose | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.